Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma
NCT02581982Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 2016
- Primary completion
- May 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in urothelial carcinoma (UC), sponsored by Wake Forest University Health Sciences. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02581982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581982.